دورية أكاديمية
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.
| العنوان: | PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies. |
|---|---|
| المؤلفون: | Lee, Elizabeth K.1 (AUTHOR) eklee@partners.org, Matulonis, Ursula A.1,2 (AUTHOR) Ursula_matulonis@dfci.harvard.edu |
| المصدر: | Cancers. Aug2020, Vol. 12 Issue 8, p2054-2054. 1p. |
| مصطلحات موضوعية: | *ANTINEOPLASTIC agents, *DNA, *DRUG resistance in cancer cells, *ENZYME inhibitors, *OVARIAN tumors, *BRCA genes, *DISEASE progression, *PHARMACODYNAMICS |
| الشركة/الكيان: | UNITED States. Food & Drug Administration |
| مستخلص: | The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use from the recurrence setting to the frontline setting. In parallel, the population developing PARPi resistance is increasing. Here we review the role of PARP, DNA damage repair, and synthetic lethality. We discuss mechanisms of resistance to PARP inhibition and how this informs on novel combinations to re-sensitize cancer cells to PARPi. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: | Academic Search Index |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
asx Academic Search Index 145186931 1181 6 Academic Journal academicJournal 1181.26696777344 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=145186931&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:asx&genre=article&issn=20726694&ISBN=&volume=12&issue=8&date=20200801&spage=2054&pages=2054-2054&title=Cancers&atitle=PARP%20Inhibitor%20Resistance%20Mechanisms%20and%20Implications%20for%20Post-Progression%20Combination%20Therapies.&id=DOI:10.3390/cancers12082054 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Lee%2C+Elizabeth+K%2E%22">Lee, Elizabeth K.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> eklee@partners.org</i><br /><searchLink fieldCode="AR" term="%22Matulonis%2C+Ursula+A%2E%22">Matulonis, Ursula A.</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<i> Ursula_matulonis@dfci.harvard.edu</i> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <searchLink fieldCode="JN" term="%22Cancers%22">Cancers</searchLink>. Aug2020, Vol. 12 Issue 8, p2054-2054. 1p. ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => *<searchLink fieldCode="DE" term="%22ANTINEOPLASTIC+agents%22">ANTINEOPLASTIC agents</searchLink><br />*<searchLink fieldCode="DE" term="%22DNA%22">DNA</searchLink><br />*<searchLink fieldCode="DE" term="%22DRUG+resistance+in+cancer+cells%22">DRUG resistance in cancer cells</searchLink><br />*<searchLink fieldCode="DE" term="%22ENZYME+inhibitors%22">ENZYME inhibitors</searchLink><br />*<searchLink fieldCode="DE" term="%22OVARIAN+tumors%22">OVARIAN tumors</searchLink><br />*<searchLink fieldCode="DE" term="%22BRCA+genes%22">BRCA genes</searchLink><br />*<searchLink fieldCode="DE" term="%22DISEASE+progression%22">DISEASE progression</searchLink><br />*<searchLink fieldCode="DE" term="%22PHARMACODYNAMICS%22">PHARMACODYNAMICS</searchLink> ) Array ( [Name] => SubjectCompany [Label] => Company/Entity [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22UNITED+States%2E+Food+%26+Drug+Administration%22">UNITED States. Food & Drug Administration</searchLink> ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use from the recurrence setting to the frontline setting. In parallel, the population developing PARPi resistance is increasing. Here we review the role of PARP, DNA damage repair, and synthetic lethality. We discuss mechanisms of resistance to PARP inhibition and how this informs on novel combinations to re-sensitize cancer cells to PARPi. [ABSTRACT FROM AUTHOR] ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.3390/cancers12082054
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 1
[StartPage] => 2054
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => UNITED States. Food & Drug Administration
[Type] => general
)
[1] => Array
(
[SubjectFull] => ANTINEOPLASTIC agents
[Type] => general
)
[2] => Array
(
[SubjectFull] => DNA
[Type] => general
)
[3] => Array
(
[SubjectFull] => DRUG resistance in cancer cells
[Type] => general
)
[4] => Array
(
[SubjectFull] => ENZYME inhibitors
[Type] => general
)
[5] => Array
(
[SubjectFull] => OVARIAN tumors
[Type] => general
)
[6] => Array
(
[SubjectFull] => BRCA genes
[Type] => general
)
[7] => Array
(
[SubjectFull] => DISEASE progression
[Type] => general
)
[8] => Array
(
[SubjectFull] => PHARMACODYNAMICS
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lee, Elizabeth K.
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Matulonis, Ursula A.
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 08
[Text] => Aug2020
[Type] => published
[Y] => 2020
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 20726694
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 12
)
[1] => Array
(
[Type] => issue
[Value] => 8
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Cancers
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |